Category: Conference Sessions

This category can only be viewed by members. To view this category, sign up by purchasing MEMBER PLUS +.

Understanding the Implications and Opportunities of CSA Draft Guidance on 21 CFR Part 11

Presented by:Stephen Cook, Sr. Director – Governance & Operational Excellence, GSK Louie Rayal, Vice President, Governance, Risk and Compliance, GSK Marc Koetter, Senior Manager Computer System Validation & IT Governance, Fresenius Medical Care Cisco Vicenty, Case for Quality Program Manager, U.S. FDA Since the release of the FDA draft on Computer Software Assurance (CSA), September […]

To access this post, you must purchase MEMBER PLUS +.

Read More »

Lean Validation Case Study – Build a Modern, Risk-based CSV Program Aligning with CSA and Part 11

Presented by: Calvin Kim, Head of Quality Systems and Validation, Samsung Biologics Suju Hwang, Senior Manager, Digital Quality & Compliance, Samsung Biologics • Gain insight on how key strategy & framework are established in consideration of risk-based approach in CSA and Part 11 requirements• Understand the importance of aligning R&R across CSV relevant processes & […]

To access this post, you must purchase MEMBER PLUS +.

Read More »

Scripted vs. Unscripted Testing – Requirements and Criticality Assessments

Presented by: Marc Koetter, Senior Manager Computer System Validation & IT Governance, Fresenius Medical Care • Understand the difference between scripted and unscripted testing• Identify variants of unscripted testing• Lear how to minimize test documentation burden whilst gaining maximum test coverage by using unscripted testing• Understand the compliance of unscripted testing with the regulations• Learn […]

To access this post, you must purchase MEMBER PLUS +.

Read More »

Establishing Critical Process Parameters, Acceptance Criteria and HealthLimits

Presented by: Cindy Duhigg, Global Validation Steward, Alcon • Application of QbD for cleaning validation• Recognition that acceptance criteria are NOT goals• Determining what qualifies as a “toxicological evaluation”?• Discerning order from the chaos of all the health-based acronymsTakeaway Tools• Case study: Establishing formal health-based exposure limits

To access this post, you must purchase MEMBER PLUS +.

Read More »